Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000333 | 0.85 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL3997753 | 0.83 | MEN1 (0.37) | ALDH1A1NPC1MEN1KMT2ARAB9A | |
| SCHEMBL3995354 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1LMNANPC1CDK2 | |
| SCHEMBL14931686 | 0.73 | HPGDS (0.56) | SMN1; SMN2CDK2MAPK1ROCK2RPS6KA5 | |
| SCHEMBL3997375 | 0.70 | NPC1 (0.51) | SMN1; SMN2NPC1CDK2MAPK1ROCK2 | |
| SCHEMBL29441039 | 0.70 | P2RX3 (0.48) | SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL1101522 | 0.69 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1LMNANPC1CDK2 | |
| SCHEMBL5968858 | 0.69 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1LMNANPC1CDK2 | |
| SCHEMBL751213 | 0.69 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1LMNANPC1CDK2 | |
| SCHEMBL5191520 | 0.68 | HPGDS (0.44) | ALDH1A1LMNANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608656-B1 | IMIDAZOTRIAZINE COMPOUNDS FOR THE TREATMENT OF CANCER DISEASES | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1608656-B1 | IMIDAZOTRIAZINE COMPOUNDS FOR THE TREATMENT OF CANCER DISEASES | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7462614-B2 | Imidazotriazine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462614-B2 | Imidazotriazine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462614-B2 | Imidazotriazine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | SMITHKLINE BEECHAM CORPORATION | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | PLK2, PLK1, CDKL5 | SMN1; SMN2 3879/4885ALDH1A1 3450/4885LMNA 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.